Identity and synonyms
FDA describes the N-acetylated 17–23 fragment; LKKTETQ is the residue sequence, not a complete description of all marketed products.
Synonyms: Thymosin beta-4 fragment · TB500 · Thymosin B4 acetate (supplier label; ambiguous)
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Peptide fragment
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Commercial identity or variant awaiting clarification.
Mechanism
Proposed repair activity cannot be inherited from full-length thymosin β4.
Evidence and critical reading
Reported scientific and empirical uses
Recovery and connective tissue
The community associates it with muscle/tendon recovery and Wolverine/GLOW/KLOW. Each product needs its declared ingredient identity, alongside the actual molecule studied by the cited source.
Human evidence
No persuasive therapeutic outcome evidence for the exact fragment was established in this review. A recruiting registration is not a positive result.
Preclinical evidence
Fragment and metabolite experiments differ; activity of one does not identify activity of another.
Critical reading and limitations
A Tβ4 eye-drop trial or a BPC+Tβ4 series does not automatically validate a TB-500 vial or blend. A handbook weekly amount is documentary information; it is not a fragment regimen when material identity is uncertain.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by 2.pdf
5–10 mg · Total weekly amount
- Frequency
- Source divides the week into 2–3 administrations without specifying allocation.
- Duration
- First two weeks of a phased source regimen.
- Route
- Source mentions SC or IM; exact compound identity unresolved.
- Context
- Source-described loading phase, not a recommendation.
- Presentation
- Not stated on selected page.
- Interpretation
- Do not interpret weekly amount as a per-administration amount. Do not transfer to an identified fragment by analogy alone.
manual07 · Page 21 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
US: no approved TB-500 product established by FDA assessment.
Adverse effects and unknowns
Human safety, interactions and chronic toxicity are inadequately characterized; identity uncertainty is material.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
TB-500 · 1 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
The printed upper limit requires source clarification; it is not accepted as a clinical regimen or silently changed to another unit. · manual01 · Page 155
Calling a synergy “documented” does not itself supply a clinical combination trial. · manual05 · Page 8
The official registry record NCT07487363 contains mock, fictional or example-study wording. It is excluded from ordinary trial listings pending source authentication. A registry entry does not establish that a genuine study was conducted or that clinical results exist. · NCT07487363
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID26056426
Sosne G, Ousler GW.
October 16, 2026
- PMID34324435
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
Lee E, Padgett B.
October 16, 2026
- R03
- R06
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- manual05
4.pdf
October 16, 2026
- manual07
2.pdf
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026
- NCT07487363
ClinicalTrials.gov NCT07487363 — source-integrity review hold
October 18, 2026